Anti-Human CD3 x GPRC5D (Talquetamab) – Fc Muted™ - 500 µg

All|Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

Anti-Human CD3 x GPRC5D bispecific antibodies offer a promising therapeutic approach formultiple myeloma (MM) by targeting both T-cells and myeloma cells. GPRC5D (G protein-coupled receptor class C group 5 member D) is expressed in about 90% of malignantplasma cells in MM patients, making it an appealing target for treatment. Studies haveshown that these bispecific antibodies effectively kill MM cells in both in vitro and in vivosettings, including in patients with relapsed or refractory disease. Their efficacy is linked tothe levels of GPRC5D expression, and they have demonstrated significant tumor growthinhibition through the recruitment of T-cells. However, resistance mechanisms, such asgenetic inactivation or epigenetic silencing of GPRC5D, have been observed in somepatients. Despite these challenges, anti-CD3 x GPRC5D bispecific antibodies hold greatpotential as a potent treatment for a broad range of MM patients, either as a standalonetherapy or in combination with other agents1-3. JNJ-64407564, also known as Talquetamab, is a first-in-class bispecific antibody targetingGPRC5D and CD3 for treating relapsed or refractory multiple myeloma (RRMM). In clinicaltrials, Talquetamab has demonstrated significant efficacy, with overall response ratesexceeding 71% in patients exposed to at least three different classes of therapy. Byredirecting T cells to attack GPRC5D-expressing myeloma cells, Talquetamab inducesstrong cytotoxic effects. The FDA granted Talquetamab accelerated approval in August 2023for treating adults with RRMM who have undergone at least four prior lines of therapy, marking it as a promising new option for patients with limited treatment alternatives2, 4, 5.

≥ 5.0 mg/ml

GPRC5D is predominantly expressed on malignant plasma cells, making it a promising target for multiple myeloma therapy.